Tirzepatide
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Tirzepatide: From Type 2 Diabetes and Weight Management to Gout
One-Sentence Summary
Tirzepatide is a once-weekly GIP/GLP-1 receptor dual agonist given by subcutaneous injection, used for type 2 diabetes and weight management. The TxGNN model predicts it may be effective for gout, but there are no registered clinical trials and only 2 publications (one narrative review and one post hoc analysis of an RCT) supporting this direction. The better-supported lead among the top predictions is osteoarthritis, with 1 clinical trial (recruiting) and 19 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records compiled for this report. Per pharmacology data, it is used for glycaemic control in type 2 diabetes and for weight management in obesity. |
| Predicted New Indication | Gout |
| TxGNN Prediction Score | 96.75% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold (gout); see the osteoarthritis comparison below |
Other top predictions (for context):
| Rank | Predicted Indication | Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Gout | 96.75% | L3 | Research question |
| 2 | Osteoarthritis | 95.92% | L3 | Proceed with Guardrails |
| 6 | Rheumatoid arthritis | 93.60% | L4 | Research question |
| 3–5, 7–10 | Pseudoachondroplasia, osteoarthritis susceptibility, benign prostatic hyperplasia, Hunter-Thompson acromesomelic dysplasia, brachyolmia, brachyolmia-amelogenesis imperfecta syndrome, myosclerosis | 92.8–94.8% | L5 | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Pharmacology records show that tirzepatide is a peptide that acts on both the GIP receptor (GIPR) and the GLP-1 receptor (GLP1R). Its established clinical effects are improved glycaemic control and substantial weight loss (about 15–20% body weight reduction in the SURMOUNT-1 trial, depending on dose).
The link to gout is mostly indirect. Obesity is a major driver of hyperuricaemia, and hyperuricaemia is the pathogenic driver of gout. Weight loss and better insulin sensitivity may lower serum uric acid, partly by reducing renal urate reabsorption. A post hoc analysis of the SURMOUNT-1 randomised placebo-controlled trial examined tirzepatide-related changes in serum uric acid and their association with weight reduction. Weight-independent effects are possible but unproven. No prospective data on gout flares are available, so this remains a hypothesis about a biomarker rather than demonstrated clinical benefit.
For osteoarthritis, the rationale is similar. Weight loss reduces mechanical joint loading and systemic inflammation, both relevant to knee osteoarthritis pain and function. This applies to obesity-associated osteoarthritis; benefit in non-obese patients is not established.
Clinical Trial Evidence
Gout: Currently no related clinical trials registered.
Osteoarthritis (second-ranked prediction):
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06191848 | Phase 4 | Recruiting | 352 | STOP KNEE-OA: randomised, double-blind, placebo-controlled trial of weekly subcutaneous tirzepatide for 72 weeks in people with obesity and knee osteoarthritis. The main aim is to see whether it reduces the number of participants needing knee replacement. No results yet (start Nov 2024; estimated completion 2037). |
Literature Evidence
Gout:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41198460 | 2026 | Post hoc analysis of RCT | Ann Rheum Dis | Tested whether tirzepatide lowers serum uric acid through weight reduction, using SURMOUNT-1 data |
| 42469142 | 2026 | Review | Nutr Metab Cardiovasc Dis | Narrative review of the link between adiposity, hyperuricaemia and gout, asking whether weight management should be a larger focus in gout care |
Osteoarthritis (selected from 19 publications; mainly reviews and analyses, not tirzepatide-specific OA trial outcomes):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41039116 | 2025 | Systematic review / network meta-analysis | Nat Med | Efficacy and safety of obesity medications, including effects on weight and obesity-related complications |
| 40953447 | 2025 | Cost-effectiveness analysis | Ann Intern Med | Cost-effectiveness of semaglutide and tirzepatide in knee osteoarthritis with obesity |
| 41548366 | 2026 | Review | Lancet | Metabolic, cardiovascular and renal benefits of incretin-based medications |
| 42546112 | 2026 | Review | Knee Surg Sports Traumatol Arthrosc | GLP-1 receptor agonists in joint arthroplasty: effects on obesity, osteoarthritis symptoms and perioperative complications |
| 39129529 | 2024 | Not classified | Expert Opin Pharmacother | Impact of approved anti-obesity medications on osteoarthritis |
Rheumatoid arthritis (indirect, class-level evidence):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40932015 | 2025 | Observational cohort (GLP-1 RA class) | ACR Open Rheumatol | Effects of GLP-1 receptor agonists on RA disease activity and cardiovascular risk profile in patients with overweight or obesity |
| 42774139 | 2026 | Mechanistic review | Rheumatol Adv Pract | The "incretin-joint axis": weight-independent mechanisms in chronic arthropathies |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16716P | MOUNJARO INJECTION 2.5MG/0.5ML | Injection, solution | Not stated in licence records |
| SIN16714P | MOUNJARO INJECTION 5MG/0.5ML | Injection, solution | Not stated in licence records |
| SIN16717P | MOUNJARO INJECTION 7.5MG/0.5ML | Injection, solution | Not stated in licence records |
| SIN16718P | MOUNJARO INJECTION 10MG/0.5ML | Injection, solution | Not stated in licence records |
| SIN16719P | MOUNJARO INJECTION 12.5MG/0.5ML | Injection, solution | Not stated in licence records |
A sixth licence, SIN16720P (15MG/0.5ML), is also valid. All six are single-ingredient products from Eli Lilly and Company.
Safety Considerations
- Drug Interactions: No drug–drug interactions were reported. The interaction query returned only the drug's pharmacological targets, the GIP receptor and the GLP-1 receptor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold (gout). Proceed with Guardrails for osteoarthritis in patients with obesity.
Rationale:
- For gout, the evidence is a prediction plus one post hoc analysis of serum uric acid and one narrative review. There are no trials of gout outcomes, so it stays a research question.
- Osteoarthritis has a direct, well-matched Phase 4 trial (NCT06191848) and a plausible weight-mediated mechanism, but the trial has no results yet. The supporting literature is mostly reviews and economic analyses.
- Rheumatoid arthritis evidence is indirect and not specific to tirzepatide. The remaining predictions (rare skeletal dysplasias, osteoarthritis susceptibility, benign prostatic hyperplasia, myosclerosis) have no trials or literature and should be held.
To proceed, the following is needed:
- Prospective data on gout flares, or a trial of tirzepatide in gout with hyperuricaemia and obesity
- Results from NCT06191848 for the osteoarthritis indication
- Detailed mechanism of action data
- Package insert warnings and contraindications from the HSA, needed before safety screening
- Approved indication text for the Singapore licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.